Neurotransmitters and Memory: Cholinergic, Glutamatergic, GaBAergic, Dopaminergic, Serotonergic, Signaling, and Memory

Identification of Neural Markers Accompanying Memory

Volumn , Issue , 2013, Pages 5-45

  Meneses, Alfredo ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Acetylcholine; Amnesia; Behavioral models of memory; Dopamine; Forgetting; GABA; Glutamate; Memory; Memory disorders; Neurotransmitters; Serotonin; Signaling; Tentative treatments for memory dysfunctions

Indexed keywords

EID: 84902580764     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-408139-0.00002-X     Document Type: Chapter

References (262)

1. Adamantidis A., de Lecea L. A role for melanin-concentrating hormone in learning and memory. Peptides 2009, 30:2066-2070.
2. Altman H.J., Normile H.J. What is the nature of the role of the serotonergic nervous system in learning and memory: prospects for development of an effective treatment strategy for senile dementia. Neurobiol. Aging 1988, 9:627-638.
3. Anggono V., Huganir R.L. Regulation of AMPA receptor trafficking and synaptic plasticity. Curr. Opin. Neurobiol. 2012, 22(3):461-469.
4. Atack J.R. GABAA receptor subtype-selective modulators. II. α5-selective inverse agonists for cognition enhancement. Curr. Top Med. Chem. 2011, 11(9):1203-1214.
5. Bakheit A.M. Drug treatment of poststroke aphasia. Expert Rev. Neurother 2004, 4(2):211-217.
6. Beaulieu J.M., Gainetdinov R.R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 2011, 63(1):182-217.
7. Bekinschtein P., Katche C., Slipczuk L., Gonzalez C., Dorman G., Cammarota M., et al. Persistence of long-term memory storage: new insights into its molecular signatures in the hippocampus and related structures. Neurotox. Res. 2010, 18(3-4):377-385.
8. Belcher A.M., O'Dell S.J., Marshall J.F. Impaired object recognition memory following methamphetamine, but not p-chloroamphetamine- or d-amphetamine-induced neurotoxicity. Neuropsychopharmacology 2005, 30(11):2026-2034.
9. Bentley P., Driver J., Dolan R.J. Cholinergic modulation of cognition: insights from human pharmacological functional neuroimaging. Prog. Neurobiol. 2011, 94(4):360-388.
10. Berger M., Gray J.A., Roth B.L. The expanded biology of serotonin. Annu. Rev. Med. 2009, 60:355-366.
11. Bockaert J., Claeysen S., Bécamel C., Dumuis A., Marin P. Neuronal 5-HT metabotropic receptors: fine-tuning of their structure, signaling, and roles in synaptic modulation. Cell Tissue Res. 2006, 326:553-572.
12. 4 Receptors: history, molecular pharmacology and brain functions. Neuropharmacol 2008, 55:922-931.
13. 4 Receptors, a place in the sun: act two. Curr. Opin. Pharmacol. 2011, 11(1):87-93.
14. Bombardi C., Di Giovanni G. Functional anatomy of 5-HT2A receptors in the amygdala and hippocampal complex: relevance to memory functions. Exp. Brain Res. 2013, 230(4):427-439.
15. Bonsi P., Cuomo D., Ding J., Sciamanna G., Ulrich S., Tscherter A., et al. Endogenous serotonin excites striatal cholinergic interneurons via the activation of 5-HT 2C, 5-HT6, and 5-HT7 serotonin receptors: implications for extrapyramidal side effects of serotonin reuptake inhibitors. Neuropsychopharmacology 2007, 32(8):1840-1854.
16. 1A receptor in relation to human cognition. Behav. Brain Res. 2008, 195(1):103-111.
17. Bosch O.G., Wagner M., Jessen F., Kühn K.U., Joe A., Seifritz E., et al. Verbal memory deficits are correlated with prefrontal hypometabolism in (18)FDG PET of recreational MDMA users. PLoS One 2013, 8(4):e61234.
18. 2C receptor antagonism is neuroanatomically specific. J. Neurosci. 2010, 30(3):930-938.
19. Bourson A., Borroni E., Austin R.H., Monsma F.J., Sleight A.J. Determination of the role of the 5-ht6 receptor in the rat brain: a study using antisense oligonucleotides. J. Pharmacol Exp. Ther. 1995, 274(1):173-180.
20. Briand L.A., Gritton H., Howe W.M., Young D.A., Sarter M. Modulators in concert for cognition: modulator interactions in the prefrontal cortex. Prog. Neurobiol. 2007, 83(2):69-91.
21. Buchhave P., Minthon L., Zetterberg H., Wallin A.K., Blennow K., Hansson O. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch. Gen. Psychiatry 2012, 69(1):98-106.
22. Bussey T.J., Holmes A., Lyon L., Mar A.C., McAllister K.A., Nithianantharajah J., et al. New translational assays for preclinical modelling of cognition in schizophrenia: the touchscreen testing method for mice and rats. Neuropharmacology 2012, 62(3):1191-1203.
23. 1A receptor agonist 8-OH-DPAT prevents prefrontocortical glutamate and serotonin release in response to blockade of cortical NMDA receptors. J. Neurochem. 2006, 96(3):853-860.
24. 6 receptor antagonist SB742457. Neuropharmacology 2012, 63(5):890-897.
25. Cammarota M., Bevilaqua L.R., Medina J.H., Izquierdo I. ERK1/2 and CaMKII-mediated events in memory formation: is 5HT regulation involved?. Behav. Brain Res. 2008, 195:120-128.
26. Carli M., Samanin R. 8-Hydroxy-2- (di-n-propylamino) tetralin impairs spatial learning in a water maze: role of postsynaptic 5-HT1A. Br. J. Pharmacol. 1992, 105:720-726.
27. 1A receptors in the hippocampus. Behav. Brain Res. 1995, 67:67-74.
28. 1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal administration of scopolamine or 7-chloro-kynurenic acid. Brain Res. 1997, 774:167-174.
29. 1A receptors in the dorsal raphe reverses the impairment caused by intrahippocampal scopolamine in rats. Eur. J. Neurosci. 1998, 10:221-230.
30. 1A receptor antagonist, prevents the impairment of spatial learning caused by blockade of hippocampal NMDA receptors. Neuropharmacology 1999, 38:1165-1173.
31. 1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine. Br. J. Pharmacol. 1999, 128:1207-1214.
32. 1A receptors. Psychopharmacology (Berl) 2000, 149:259-268.
33. 1A receptors in the dorsal raphe ameliorates the impairment of spatial learning caused by intrahippocampal 7-chloro-kynurenic acid in naive and pretrained rats. Psychopharmacology (Berl) 2001, 158(1):39-47.
34. 2A receptors in the medial prefrontal cortex to different aspects of executive control such as impulsivity and compulsive perseveration in rats. Neuropsychopharmacol 2006, 31:757-767.
35. Choi Y.H., Kang H., Lee W.K., Kim T., Rhim H., Yu Y.G. An inhibitory compound against the interaction between G alpha(s) and the third intracellular loop region of serotonin receptor subtype 6 (5-HT6) disrupts the signaling pathway of 5-HT6. Exp. Mol. Med. 2007, 39(3):335-342.
36. Collingridge G.L., Volianskis A., Bannister N., France G., Hanna L., Mercier M., et al. The NMDA receptor as a target for cognitive enhancement. Neuropharmacology 2013, 64:13-26.
37. Cook R.G., Geller A.I., Zhang G.R., Gowda R. Touchscreen-enhanced visual learning in rats. Behav. Res. Methods Instrum. Comput. 2004, 36(1):101-106.
38. Cooper J.R., Bloom F.E., Roth R.H. The Biochemical Basis of Neuropharmacology 2003, Oxford University Press, New York, NY.
39. Costa-Mattioli M., Sonenberg N. Translational control of gene expression: a molecular switch for memory storage. Prog. Brain Res. 2008, 169:81-95.
40. Coultrap S.J., Bayer K.U. CaMKII regulation in information processing and storage. Trends Neurosci. 2012, 35(10):607-618.
41. Cowen P., Sherwood A.C. The role of serotonin in cognitive function: evidence from recent studies and implications for understanding depression. J. Psychopharmacol. 2013, 27(7):575-578.
42. Cummings J., Gould H., Zhong K. Advances in designs for Alzheimer's disease clinical trials. Am. J. Neurodegener. Dis. 2012, 1(3):205-216.
43. Czubak A., Nowakowska E., Burda K., Kus K., Metelska J. Cognitive effects of GABAergic antiepileptic drugs. Arzneimittelforschung 2010, 60(1):1-11.
44. 6 Receptor blockade differentially affects scopolamine-induced deficits of working memory, recognition memory and aversive learning in mice. Psychopharmacology (Berl.) 2012, 222(1):99-115.
45. Dalley J.W., Lääne K., Theobald D.E., Armstrong H.C., Corlett P.R., Chudasama Y., et al. Time-limited modulation of appetitive Pavlovian memory by D1 and NMDA receptors in the nucleus accumbens. Proc. Natl. Acad. Sci. USA 2005, 102(17):6189-6194.
46. Davis H.P., Squire L.R. Protein synthesis and memory: a review. Psychol. Bull. 1984, 96(3):518-559.
47. de Boissezon X., Peran P., de Boysson C, Démonet J.F. Pharmacotherapy of aphasia: myth or reality?. Brain Lang. 2007, 102(1):114-125.
48. de Foubert G., O'Neill M.J., Zetterström T.S. Acute onset by 5-HT(6)-receptor activation on rat brain brain-derived neurotrophic factor and activity-regulated cytoskeletal-associated protein mRNA expression. Neuroscience 2007, 147(3):778-785.
49. Decker M.W., McGaugh J.L. The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse 2004, 7(2):151-168.
50. Dougherty J.P., Oristaglio J. Chronic treatment with the serotonin 2A/2C receptor antagonist SR 46349B enhances the retention and efficiency of rule-guided behavior in mice. Neurobiol. Learn. Memory 2013, 103:50-63.
51. Dudanova I., Klein R. Integration of guidance cues: parallel signaling and crosstalk. Trends Pharmacol. Sci. 2013, 36(5):295-304.
52. Eichenbaum H. What H.M. taught us. J. Cogn. Neurosci. 2013, 25(1):14-21.
53. 1A and NMDA receptors interact in the rat medial septum and modulate hippocampal-dependent spatial learning. Hippocampus 2009, 19(12):1187-1198.
54. Engelborghs S., Sleegers K., Van der Mussele S., Le Bastard N., Brouwers N., Van Broeckhoven C., et al. Brain-Specific tryptophan hydroxylase, TPH2, and 5-HTTLPR are associated with frontal lobe symptoms in Alzheimer's disease. J. Alzheimers Dis. 2013, 35(1):67-73.
55. Eppinger B., Hämmerer D., Li S.C. Neuromodulation of reward-based learning and decision making in human aging. Ann. NY Acad. Sci. 2012, 1235:1-17.
56. 7 Receptor crosstalk in the regulation of emotional memory: Implications for effects of selective serotonin reuptake inhibitors. Neuropharmacology 2012, 63(6):1150-1160.
57. Ersche K.D., Roiser J.P., Lucas M., Domenici E., Robbins T.W., Bullmore E.T. Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment. Psychopharmacology (Berl.) 2011, 214(4):779-789.
58. Euston D.R., Gruber A.J., McNaughton B.L. The role of medial prefrontal cortex in memory and decision making. Neuron 2012, 76(6):1057-1070.
59. Farrant M. Amino acids: inhibitory. Neurotransmitters, Drugs and Brain Function 2001, John Wiley & Sons, Chichester, UK. R.A. Webster (Ed.).
60. Fletcher L. Memories are made of this: the genetic basis of memory. Mol. Med. Today 1997, 3(10):429-434.
61. Fink K.B., Göthert M. 5-HT Receptor regulation of neurotransmitter release. Pharmacol. Rev. 2007, 59(4):360-417.
62. Fournet V., de Lavilléon G., Schweitzer A., Giros B., Andrieux A., Martres M.P. Both chronic treatments by epothilone D and fluoxetine increase the short-term memory and differentially alter the mood-status of STOP/MAP6 KO mice. J. Neurochem. 2012, 123(6):982-996.
63. Frankland P.W., Köhler S., Josselyn S.A. Hippocampal neurogenesis and forgetting. Trends Neurosci. 2013, 36(9):497-503.
64. Froestl W., Muhs A., Pfeifer A. Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors. J. Alzheimers Dis. 2012, 32(4):793-887.
65. Froestl W., Pfeifer A., Muhs A. Cognitive enhancers (nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. Disease-modifying drugs. J. Alzheimers Dis. 2013, 34(1):1-114.
66. Gacsályi I., Nagy K., Pallagi K., Lévay G., Hársing L.G., Móricz K., et al. Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents. Neuropharmacology 2013, 64:254-263.
67. 6 receptors in cognitive and non-cognitive symptoms in Alzheimer's disease. Neuropsychopharmacology 2004, 29:410-416.
68. 6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease. Expert Rev. Neurother. 2009, 9:1073-1085.
69. Gonda X. Basic pharmacology of NMDA receptors. Curr. Pharm. Des. 2012, 18(12):1558-1567.
70. Gong P., Zheng Z., Chi W., Lei X., Wu X., Chen D., et al. An association study of the genetic polymorphisms in 13 neural plasticity-related genes with semantic and episodic memories. J. Mol. Neurosci. 2012, 46(2):352-361.
71. Graef S., Schönknecht P., Sabri O., Hegerl U. Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: an overview of preclinical and clinical findings. Psychopharmacology (Berl.) 2011, 215(2):205-229. <10.1007/s00213-010-2153-8>. Epub 2011 Jan 8.
72. Gräff J., Tsai L.H. Histone acetylation: molecular mnemonics on the chromatin. Nat. Rev. Neurosci. 2013, 14(2):97-111.
73. Gravius A., Laszy J., Pietraszek M., Sághy K., Nagel J., Chambon C., et al. Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity. Behav. Pharmacol. 2011, 22(2):122-135.
74. Guan Z., Giustetto M., Lomvardas S., Kim J.H., Miniaci M.C., Schwartz J.H., et al. Integration of long-term-memory-related synaptic plasticity involves bidirectional regulation of gene expression and chromatin structure. Cell 2002, 111(4):483-493.
75. Gupta A., Hemraj, Jalhan S., Jindal A., Upmanyu N. Various animal models to check learning and memory-a review. Int. J. Pharm. Pharm. Sci. 2012, 4(Suppl. 3):91-95.
76. 4 receptor levels in hippocampus correlates inversely with memory test performance in humans. Hum. Brain Mapp. 2012, 34(11):3066-3074.
77. Haas C. Strategies, development, and pitfalls of therapeutic options for Alzheimer's disease. J. Alzheimers Dis. 2012, 28(2):241-281.
78. 1A receptors on learning and memory functions in rats. Neurochem. Res. 2012, 37(10):2161-2166. http://www.ncbi.nlm.nih.gov/pubmed/22814880.
79. Hajjo R., Setola V., Roth B.L., Tropsha A. Chemocentric informatics approach to drug discovery: identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers. J. Med. Chem. 2012, 55(12):5704-5719.
80. Hermann A., Küpper Y., Schmitz A., Walter B., Vaitl D., Hennig J., et al. Functional gene polymorphisms in the serotonin system and traumatic life events modulate the neural basis of fear acquisition and extinction. PLoS One 2012, 7(9):e44352.
81. Hernandez C.M., Dineley K.T. α7 Nicotinic acetylcholine receptors in Alzheimer's disease: neuroprotective, neurotrophic or both?. Curr. Drug Targets 2012, 13(5):613-622.
82. 2C receptor knockout mice. Hippocampus 2011, 21(4):434-445.
83. Hindi Attar C., Finckh B., Büchel C. The influence of serotonin on fear learning. PLoS One 2012, 7(8):e42397.
84. 6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur. J. Pharmacol. 2006, 553(1-3):109-119.
85. Hong E, Orozco G, Meneses A, Fillion G. Effect of 5-HT-moduline, an endogenous peptide, in associative learning. Proc. West. Pharmacol. Soc. 1999, 42:37-38.
86. 3 compounds on learning. Pharmacol. Biochem. Behav. 1996, 53(4):765-769.
87. 3 receptor antagonists WAY-100579 and ondansetron on spatial learning in the water maze in rats with excitotoxic lesions of the forebrain cholinergic projection system. Psychopharmacol (Berl) 1996, 125(2):146-161.
88. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., et al. International union of pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev. 1994, 46(2):157-203.
89. Hoyer D., Hannon J.P., Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 2002, 7:533-554.
90. 6 receptor mRNA expression during memory consolidation and amnesia. Neurobiol. Learn. Mem. 2010, 93(1):99-110.
91. Ivachtchenko A.V., Ivanenkov Y.A. 5HT6 receptor antagonists: a patent update. Part 1. Sulfonyl derivatives. Expert Opin. Ther. Pat. 2012, 22(8):917-964.
92. Ivachtchenko A.V., Ivanenkov Y.A., Skorenko A.V. 5-HT6 Receptor modulators: a patent update. Part 2. Diversity in heterocyclic scaffolds. Expert Opin. Ther. Pat. 2012, 22(10):1123-1168.
93. Izquierdo I., Cunha C., Medina J.H. Endogenous benzodiazepine modulation of memory processes. Neurosci. Biobehav. Rev. 1990, 14(4):419-424.
94. Izquierdo I., Medina J.H., Vianna M.R., Izquierdo L.A., Barros D.M. Separate mechanisms for short- and long-term memory. Behav. Brain Res. 1999, 103(1):1-11.
95. Izquierdo I., Bevilaqua L.R., Rossato J.I., Bonini J.S., Medina J.H., Cammarota M. Different molecular cascades in different sites of the brain control memory consolidation. Trends Neurosci. 2006, 29(9):496-505.
96. Izquierdo I., McGaugh J.L. Behavioural pharmacology and its contribution to the molecular basis of memory consolidation. Behav. Pharmacol. 2000, 11(7-8):517-534.
97. Jane D.E., Lodge D., Collingridge G.L. Kainate receptors: pharmacology, function and therapeutic potential. Neuropharmacology 2009, 56(1):90-113.
98. Jarome T.J., Lubin F.D. Histone lysine methylation: critical regulator of memory and behavior. Rev. Neurosci. 2013, 27:1-13.
99. Jones T., Moller M.D. Implications of hypothalamic-pituitary-adrenal axis functioning in posttraumatic stress disorder. J. Am. Psychiatry Nurses Assoc. 2011, 17(6):393-403.
100. Kandel E.R. The molecular biology of memory storage: a dialogue between genes and synapses. Science 2001, 294:1030-1038.
101. Kandel E.R. The molecular biology of memory: cAMP, PKA, CRE, CREB-1, CREB-2, and CPEB. Mol. Brain 2012, 5:14.
102. Kemp A., Manahan-Vaughan D. Hippocampal long-term depression: master or minion in declarative memory processes?. Trends Neurosci. 2007, 30(3):111-118.
103. 7 antagonists with increased In vitro metabolic stability. Bioorg. Med. Chem. Lett. 2003, 13(1):61-64.
104. 6 receptors in learning and memory. Trends Pharmacol. Sci. 2008, 29:482-492.
105. Klinkenberg I., Blokland A. The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neurosci. Biobehav. Rev. 2010, 34(8):1307-1350.
106. Koenig P., Smith E.E., Troiani V., Anderson C., Moore P., Grossman M. Medial temporal lobe involvement in an implicit memory task: evidence of collaborating implicit and explicit memory systems from FMRI and Alzheimer's disease. Cereb Cortex. 2009, 18:2831-2843.
107. Koh M.T. Pharmacological treatment strategies targeting cognitive impairment associated with aging. Nihon Yakurigaku Zasshi 2012, 139(4):157-159. (Article in Japanese).
108. Lanctôt K.L., Herrmann N., Black S.E., Ryan M., Rothenburg L.S., Liu B.A., et al. Apathy associated with Alzheimer disease: use of dextroamphetamine challenge. Am. J. Geriatr. Psychiatry 2008, 16(7):551-557.
109. Lesch K.P., Waider J. Serotonin in the modulation of neural plasticity and networks: implications for neurodevelopmental disorders. Neuron 2012, 76(1):175-191.
110. 6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat. Neuropsychopharmacology 2005, 30(12):2169-2179.
111. Lindner M.D., Hodges D.B., Hogan J.B., Orie A.F., Corsa J.A., Barten D.M., et al. An assessment of the effects of serotonin 6 (5-HT6) receptor antagonists in rodent models of learning. J. Pharmacol. Exp. Ther. 2003, 307(2):682-691.
112. 6 Antagonists as potential treatment for cognitive dysfunction. Drug Dev. Res. 2009, 70:145-168.
113. 1-7 receptors in short- and long-term memory for an autoshaping task: intrahippocampal manipulations. Brain Res. 2008, 1147:140-147.
114. 1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons. Cereb. Cortex 2012, 22(7):1487-1497.
115. 6 receptors in the prefrontal cortex of Alzheimer and normal aging patients. BMC Neurosci. 2006, 7:36.
116. 6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem. 2013, 4:191-199.
117. Lynch G. Glutamate-based therapeutic approaches: ampakines. Curr. Opin. Pharmacol. 2006, 6(1):82-88.
118. Lynch G., Palmer L.C., Gall C.M. The likelihood of cognitive enhancement. Pharmacol. Biochem. Behav. 2011, 99(2):116-129.
119. Lynch M.A. Long term potentiation. Physiol. Rev. 2004, 84:87-136.
120. Lyseng-Williamson, K., 2013. Clozapine: a guide to its use in patients with schizophrenia who are unresponsive to or intolerant of other antipsychotic agents. Drug Ther. Perspect. 29, 161-165.
121. Maffei A. The many forms and functions of long term plasticity at GABAergic synapses. Neural Plast. 2011, 254724. 9 pages.
122. Mansour A.R., Farmer M.A., Baliki M.N., Apkarian A.V. Chronic pain: the role of learning and brain plasticity. Restor Neurol. Neurosci. 2013, [Epub ahead of print] PMID: 23603439.
123. Manuel-Apolinar L., Meneses A. 8-OH-DPAT facilitated memory consolidation and increased hippocampal and cortical cAMP production. Behav. Brain Res. 2004, 148(1-2):179-184.
124. Marazziti D., Baroni S., Catena Dell'Osso M., Bordi F, Borsini F. Serotonin receptors of type 6 (5-HT6): what can we expect from them?. Curr. Med. Chem. 2011, 18(18):2783-2790.
125. Marazziti D., Baroni S., Borsini F., Picchetti M., Vatteroni E., Falaschi V., et al. Serotonin receptors of type 6 (5-HT6): from neuroscience to clinical pharmacology. Curr. Med. Chem. 2013, 20(3):371-377.
126. 6 receptor-mediated acetylcholine release. Eur. J. Neurosci. 2006, 24:299-1306.
127. 6 receptor function in behavioral symptoms of Alzheimer's disease. J. Alzheimers Dis. 2008, 14:43-50.
128. 6 receptors: relevance for cognitive effects. Int. J. Neuropsychopharmacol. 2010, 9:1-10.
129. Marin P., Meffre J., Chaumont-Dubel S., La Cour C.L., Loiseau F., Watson D.J.G., et al., 2012a. 5-HT6 Receptors disrupt cognition by recruiting mTOR: relevance to schizophrenia. Serotonin Club meeting, Abstract p. 58. July 10-12, Montpellier, France.
130. Marin P., Becamel C., Dumuis A., Bockaert J. 5-HT Receptor-associated protein networks: new targets for drug discovery in psychiatric disorders?. Curr. Drug Targets 2012, 13(1):28-52.
131. Marshall J.F., O'Dell S.J. Methamphetamine influences on brain and behavior: unsafe at any speed?. Trends Neurosci. 2012, 35(9):536-545.
132. Martin C., Sibson N.R. Pharmacological MRI in animal models: a useful tool for 5-HT research?. Neuropharmacology 2008, 55:1038-1047.
133. Martyn A.C., De Jaeger X., Magalhães A.C., Kesarwani R., Gonçalves D.F., Raulic S., et al. Elimination of the vesicular acetylcholine transporter in the forebrain causes hyperactivity and deficits in spatial memory and long-term potentiation. Proc. Natl. Acad. Sci. USA 2012, 109(43):17651-17656.
134. Mathur B.N., Lovinger D.M. Serotonergic action on dorsal striatal function. Parkinsonism Relat. Disord. 2012, 18(Suppl. 1):S129-S131.
135. Mayford M., Siegelbaum S.A., Kandel E.R. Synapses and memory storage. Cold. Spring. Harb. Perspect. Biol. 2012, 4(6):1-18.
136. McGaugh J.L. Drug facilitation of learning and memory. Annu. Rev. Pharmacol. 1973, 13:229-241.
137. McGaugh J.L. Dissociating learning and performance: drug and hormone enhancement of memory storage. Brain Res. Bull. 1989, 23(4-5):339-345.
138. McGaugh J.L. Make mild moments memorable: add a little arousal. Trends Cogn. Sci. 2006, 10:345-347.
139. McGaugh J.L. Making lasting memories: remembering the significant. Proc. Natl. Acad. Sci. USA 2013, 110(Suppl 2):10402-10407.
140. McGaugh J.L., Izquierdo I. The contribution of pharmacology to research on the mechanisms of memory formation. Trends Pharmacol. Sci. 2000, 21(6):208-210.
141. Means A.R. The year in basic science: calmodulin kinase cascades. Mol. Endocrinol. 2008, 22(12):2759-2765.
142. Menard J., Treit D. Effects of centrally administered anxiolytic compounds in animal models of anxiety. Neurosci. Biobehav. Rev. 1999, 23(4):591-613.
143. Meltzer H.Y. Update on typical and atypical antipsychotic drugs. Annu. Rev. Med. 2013, 64:393-406.
144. Meneses A. 5-HT System and cognition. Neurosci. Biobehav. Rev. 1999, 23:1111-1125.
145. 6 receptor antagonist Ro 04-6790 on learning consolidation. Behav. Brain Res. 2001, 118(1):107-110.
146. (1-7) receptors modulate memory formation in an autoshaping Pavlovian/instrumental task. Neurosci. Biobehav. Rev. 2002, 26(3):309-319.
147. 7 receptor subtypes function on a Pavlovian/instrumental autoshaped memory. Learn. Mem. 2003, 10:363-372.
148. 4 receptors or 5-HT uptake inhibition: short- and long-term memory. Behav. Brain Res. 2007, 184:81-90.
149. 1-7 receptors modulate short and long-term memory?. Neurobiol. Learn. Mem. 2007, 87:561-572.
150. 1A receptors modulate the consolidation of learning in normal and cognitively impaired rats. Neurobiol. Learn. Mem. 1999, 71(2):207-218.
151. Meneses A., Hong E. A pharmacological analysis of serotonergic receptors: effects of their activation of blockade in learning. Prog. Neuropsychopharmacol. Biol. Psychiatry 1997, 21(2):273-296.
152. Meneses A. 5-HT systems: emergent targets for memory formation and memory alterations. Rev. Neurosci 2013, (in press).
153. Meneses A., Liy-Salmeron G. Serotonin and emotion, learning and memory. Rev. Neurosci. 2012, 23:443-453.
154. 1A Receptors and memory. Neurosci. Biobehav. Rev. 2007, 31(5):705-727.
155. 6 receptors expression in rat brain: an autoradiographic study. Behav. Brain Res. 2007, 178:53-61.
156. Meneses A., Perez-Garcia G., Liy-Salmeron G., Ponce-Lopez T., Tellez R., Flores-Galvez D. Associative learning, memory and serotonin: a neurobiological and pharmacological analysis. Models of Neuropharmacology 2009, 169-182. Transworld Research Network, Trivandrum, India. L.L. Rocha Arrieta, V. Granados-Soto (Eds.).
157. 6 Receptor memory and amnesia: behavioral pharmacology-learning and memory processes. Int. Rev. Neurobiol. 2011, 96:27-47.
158. Meneses A., Perez-Garcia G., Ponce-Lopez T., Tellez R., Castillo C. Serotonin transporter and memory. Neuropharmacology 2011, 61(3):355-363.
159. Meyer J.H. Neuroimaging markers of cellular function in major depressive disorder: implications for therapeutics, personalized medicine, and prevention. Clin. Pharmacol. Ther. 2012, 91(2):201-214.
160. Millan M.J., Gobert A., Roux S., Porsolt R., Meneses A., Carli M., et al. The serotonin1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis. J. Pharmacol. Exp. Ther. 2004, 311(1):190-203.
161. Millan M.J., Agid Y., Brüne M., Bullmore E.T., Carter C.S., Clayton N.S., et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat. Rev. Drug Discov. 2012, 11(2):141-168.
162. 6 receptors in the rat dorsomedial striatum impairs instrumental learning. Neuropsychopharmacology 2007, 32:1520-1530.
163. Mitchell E.S., McDevitt R.A., Neumaier J.F. Adaptations in 5-HT receptor expression and function: implications for treatment of cognitive impairment in aging. J. Neurosci. Res. 2009, 87(12):2803-2811.
164. Monje F.J., Divisch I., Demit M., Lubec G., Pollak D.D. Flotillin-1 is an evolutionary-conserved memory-related protein up-regulated in implicit and explicit learning paradigms. Ann. Med. 2013, 45(4):301-307.
165. Moret C., Grimaldi B., Massot O., Fillion G. The role and therapeutic potential of 5-HT-moduline in psychiatry. Semin Clin Neuropsychiatr 2003, 8(2):137-146.
166. Morris R.G. NMDA receptors and memory encoding. Neuropharmacology 2013, 74:32-40.
167. Myhrer T. Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks. Brain Res. Rev. 2003, 41:268-287.
168. 1A receptors and memory. Neurosci. Biobehav. Rev. 2007, 31(5):705-727.
169. Na C.H., Jones D.R., Yang Y., Wang X., Xu Y., Peng J. Synaptic protein ubiquitination in rat brain revealed by antibody-based ubiquitome analysis. J. Proteome Res. 2012, 11(9):4722-4732.
170. Niciu M.J., Kelmendic B., Sanacora G. Overview of glutamatergic neurotransmission in the nervous system. Pharmacol. Biochem. Behav. 2012, 100:656-664.
171. Nonkes L.J., Maes J.H., Homberg J.R. Improved cognitive flexibility in serotonin transporter knockout rats is unchanged following chronic cocaine self-administration. Addict. Biol. 2013, 18(3):434-440.
172. Nordquist N., Oreland L. Serotonin, genetic variability, behaviour, and psychiatric disorders-a review. Ups. J. Med. Sci. 2010, 115(1):2-10.
173. Noristani H.N., Verkhratsky A., Rodríguez J.J. High tryptophan diet reduces CA1 intraneuronal β-amyloid in the triple transgenic mouse model of Alzheimer's disease. Aging Cell 2012, 11(5):810-822.
174. 1A receptors in learning and memory. Behav. Brain Res. 2008, 195:54-77.
175. Olsen R.W., Sieghart W. International union of pharmacology. LXX. Subtypes of γ-aminobutyric acid receptors: classification on the basis of subunit composition, pharmacology, and function. Update Pharmacol. Rev. 2008, 60(3):243-260.
176. Oscos A., Martinez J.L., McGaugh J.L. Effects of post-training d-amphetamine on acquisition of an appetitive autoshaped lever press response in rats. Psychopharmacology (Berl.) 1988, 95(1):132-134.
177. Paille V., Fino E., Du K., Morera-Herreras T., Perez S., Kotaleski J.H., et al. GABAergic circuits control spike-timing-dependent plasticity. J. Neurosci. 2013, 33(22):9353-9363.
178. Packard M.G., Knowlton B.J. Learning and memory functions of the Basal Ganglia. Annu. Rev. Neurosci. 2002, 25:563-593.
179. Pattij, T., 2002. "5-HT1A receptor knockout mice and anxiety: Behavioral and physiological studies." Ph.D. thesis, Universiteit Utrecht, The Netherlands.
180. Peele D.B., Vincent A. Strategies for assessing learning and memory, 1978-1987: a comparison of behavioral toxicology, psychopharmacology, and neurobiology. Neurosci. Biobehav. Rev. 1989, 13(4):317-322.
181. Peixoto L., Abel T. The role of histone acetylation in memory formation and cognitive impairments. Neuropsychopharmacology 2013, 38(1):62-76.
182. 2C receptors on executive control processes. Neuropsychopharmacology 2013, 38(6):957-967.
183. Pérez-García G., Meneses A. Memory formation, amnesia, improved memory and reversed amnesia: 5-HT role. Behav. Brain Res. 2008, 195:17-29.
184. 7 receptor agonists and antagonists on cAMP accumulation during memory formation and amnesia. Behav. Brain Res. 2008, 195:139-146.
185. 7 receptors during memory consolidation. Behav. Brain Res. 2006, 169(2006):83-92.
186. 7 receptors. Behav. Brain Res. 2009, 202:102-113.
187. Prado-Alcalá R.A., Ruiloba M.I., Rubio L., Solana-Figueroa R., Medina C., Salado-Castillo R., et al. Regional infusions of serotonin into the striatum and memory consolidation. Synapse. 2003, 47(3):169-175.
188. Puig M.V., Gulledge A.T. Serotonin and prefrontal cortex function: neurons, networks, and circuits. Mol. Neurobiol. 2011, 44(3):449-464.
189. Radley J.J., Farb C.R., He Y., Janssen W.G., Rodrigues S.M., Johnson L.R., et al. Distribution of NMDA and AMPA receptor subunits at thalamo-amygdaloid dendritic spines. Brain Res. 2007, 1134:87-94.
190. Rahn E.J., Guzman-Karlsson M.C., Sweatt J. Cellular, molecular, and epigenetic mechanisms in non-associative conditioning: implications for pain and memory. Neurobiol. Learn. Mem. 2013, 105:133-150.
191. Rajasethupathy P., Antonov I., Sheridan R., Frey S., Sander C., Tuschl T., et al. A role for neuronal piRNAs in the epigenetic control of memory-related synaptic plasticity. Cell 2012, 149(3):693-707.
192. 6 Receptors and Alzheimer's disease. Alzheimer's Res. Ther. 2013, 5:15-23.
193. Raymond J.R., Mukhin Y.V., Gelasco A., Turner J., Collinsworth G., Gettys T.W., et al. Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol. Ther. 2001, 92(2-3):179-212.
194. Raymond J.R., Turner J.H., Gelasco A.K., Ayiku H.B., Coaxum S.D., Arthur J.M., et al. The Serotonin Receptors 2006, 143-206. Human Press, Totowa, NJ. B.L. Roth (Ed.).
195. 6 antagonists. Bioorg. Med. Chem. Lett. 2010, 20(12):3713-3716.
196. Reis H.J., Guatimosim C., Paquet M., Santos M., Ribeiro F.M., Kummer A., et al. Neuro-transmitters in the central nervous system and their implication in learning and memory processes. Curr. Med. Chem. 2009, 16(7):796-840.
197. 7 receptor in learning and memory. Hippocampus 2012, 22(4):762-771.
198. Roberts P.D., Spiros A., Geerts H. Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action. Alzheimers Res. Ther. 2012, 4(6):50. [Epub ahead of print] PMID: 23181523.
199. Rodríguez J.J., Noristani H.N., Verkhratsky A. The serotonergic system in ageing and Alzheimer's disease. Prog. Neurobiol. 2012, 99:15-41.
200. 6 receptor-mediated cAMP signaling pathways. Br. J. Pharmacol. 2006, 148:1133-1143.
201. Roopra A., Dingledine R., Hsieh J. Epigenetics and epilepsy. Epilepsia 2012, 53(Suppl. 9):2-10.
202. Roozendaal B., McGaugh J.L. Memory modulation. Behav. Neurosci. 2011, 125(6):797-824.
203. 6 Receptor antagonists as potential therapeutics for cognitive impairment. Curr. Top. Med. Chem. 2010, 10:207-221.
204. Roth B.L., Hanizavareh S.M., Blum A.E. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl.) 2004, 174:17-24.
205. Ruiz N.V., Oranias G.O., 2010. Patents. In: Borsini, F. (Ed.), Int. Rev. Neurobiol. 5-HT6 Receptors, Part I, Elsevier, Academic Press, Oxford, pp. 36-66.
206. Ruotsalainen S., Miettinen R., MacDonald E., Riekkinen M., Sirviö J. The role of the dorsal raphe-serotonergic system and cholinergic receptors in the modulation of working memory. Neurosci. Biobehav. Rev. 1998, 22(1):21-31.
207. Sarter M., Hagan J., Dudchenko P. Behavioral screening for cognition enhancers: from indiscriminate to valid testing: part I. Psychopharmacology (Berl.) 1992, 107(2-3):144-159.
208. 3 receptor antagonist, enhances object exploration in intact female rats. Behav. Pharmacol. 2012, 23(8):806-809.
209. Schechter L.E., Smith D.L., Rosenzweig-Lipson S., Sukoff S.J., Dawson L.A., Marquis K., et al. Lecozotan (SRA-333): A selective serotonin1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J. Exp. Pharmacol. Ther. 2005, 314:1274-1289.
210. Schliebs R., Arendt T. The cholinergic system in aging and neuronal degeneration. Behav. Brain Res. 2011, 221(2):555-563.
211. 6 receptor antagonist RO4368554 in rat models for cognition and sensorimotor gating. Eur. Neuropsychopharmacol. 2007, 17(4):277-288.
212. Skelton M.R., Williams M.T., Vorhees C.V. Developmental effects of 3,4-methylenedioxymethamphetamine: a review. Behav. Pharmacol. 2008, 19(2):91-111.
213. Sossin W.S. Defining memories by their distinct molecular traces. Trends Neurosci. 2008, 31:170-175.
214. Spiegel D.R., Alexander G. A case of nonfluent aphasia treated successfully with speech therapy and adjunctive mixed amphetamine salts. J. Neuropsychiatry Clin. Neurosci. 2011, 23(1):E24.
215. Squire L.R., Davis H.P. The pharmacology of memory: a neurobiological perspective. Annu. Rev. Pharmacol. Toxicol. 1981, 21:323-356.
216. Squire L.R., Zola S.M. Structure and function of declarative and nondeclarative memory systems. Proc. Natl. Acad. Sci. USA 1996, 93(24):13515-13522.
217. Stahlman W.D., Young M.E., Blaisdell A.P. Response variability in pigeons in a Pavlovian task. Learn. Behav. 2010, 38(2):111-118.
218. Steckler T., Sahgal A. The role of serotonergic-cholinergic interactions in the mediation of cognitive behaviour. Behav. Brain Res. 1995, 67:165-199.
219. Stern S.A., Alberini C.M. Mechanisms of memory enhancement. Wiley. Interdiscip Rev. Syst. Biol. Med. 2013, 5(1):37-53.
220. Sweatt J.D. Experience-dependent epigenetic modifications in the central nervous system. Biol. Psychiatry 2009, 65:191-197.
221. Takahashi H., Yamada M., Suhara T. Functional significance of central D1 receptors in cognition: beyond working memory. J. Cereb. Blood Flow Metab. 2012, 32(7):1248-1258.
222. Talpos J.C., Fletcher A.C., Circelli C., Tricklebank M.D., Dix S.L. The pharmacological sensitivity of a touchscreen-based visual discrimination task in the rat using simple and perceptually challenging stimuli. Psychopharmacology (Berl.) 2012, 221(3):437-449.
223. Telese F., Gamliel A., Skowronska-Krawczyk D., Garcia-Bassets I., Rosenfeld M.G. "Seq-ing" insights into the epigenetics of neuronal gene regulation. Neuron 2013, 77(4):606-623.
224. Tellez R., Rocha L., Castillo C., Meneses A. Autoradiographic study of serotonin transporter during memory formation. Behav. Brain Res. 2010, 212(1):12-26.
225. Tellez R., Gómez-Víquez L., Meneses A. GABA glutamate, dopamine and serotonin transporters expression on memory formation and amnesia. Neurobiol. Learn. Mem. 2012, 97(2):189-201.
226. Tellez R., Gómez-Viquez L., Liy-Salmeron G., Meneses A. GABA glutamate, dopamine and serotonin transporters expression on forgetting. Neurobiol. Learn. Mem. 2012, 98(1):66-77.
227. Terry A.V., Buccafusco J.J., Wilson C. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets. Behav. Brain Res. 2008, 195:30-38.
228. Terry A.V., Callahan P.M., Hall B., Webster S.J. Alzheimer's disease and age-related memory decline (preclinical). Pharmacol. Biochem. Behav. 2011, 99(2):190-210.
229. Thellier M., Lüttge U. Plant memory: a tentative model. Plant Biol. (Stuttg.) 2013, 15(1):1-12.
230. 3 receptor pharmacology. Pharmacol. Sci. 2013, 34(2):100-109.
231. Timotijević I., Stanković Ž., Todorović M., Marković S.Z., Kastratović D.A. Serotonergic organization of the central nervous system. Psychiatr. Danub. 2012, 201(Suppl. 3):S326-S330.
232. Atlas of Neuroactive Substances and Their Receptors in the Rat 1998, Oxford University Press, Oxford. M. Tohyama, K. Takatsuji, S.S. Kantha (Eds.).
233. Tomie A., Lincks M., Nadarajah S.D., Pohorecky L.A., Yu L. Pairings of lever and food induce Pavlovian conditioned approach of sign-tracking and goal-tracking in C57BL/6 mice. Behav. Brain Res. 2012, 226(2):571-578.
234. Tremblay M.A., Acker C.M., Davies P. Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase, Arg. J. Alzheimers Dis. 2010, 19:721-733.
235. Tsuruoka N., Beppu Y., Koda H., Doe N., Watanabe H., Abe K. A DKP cyclo(L-Phe-L-Phe) found in chicken essence is a dual inhibitor of the serotonin transporter and acetylcholinesterase. PLoS One 2012, 7(11):e50824. <10.1371/journal.pone.0050824> Epub 2012 Nov 28.
236. Turner J.N., Coaxum S.D., Gelasco A.K., Garnovskaya M.N., Raymond J.R. Calmodulin is a 5-HT receptor-interacting and regulatory protein. Serotonin Receptors in Neurobiology 2007, CRC Press, Boca Raton, FL, Chapter 4 Available from: . A. Chattopadhyay (Ed.).
237. 6 Receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. Neurotherapeutics 2008, 5:458-469.
238. van Praag H.M. The cognitive paradox in posttraumatic stress disorder: a hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28(6):923-935.
239. Vanover K.E., Barrett J.E. An automated learning and memory model in mice: pharmacological and behavioral evaluation of an autoshaped response. Behav. Pharmacol. 1998, 9(3):273-283.
240. Vermetten E., Lanius R.A. Biological and clinical framework for posttraumatic stress disorder. Handbook of Clinical Neurology 2012, vol. 106. pp. 291-342.
241. Vianna M.R., Izquierdo L.A., Barros D.M., Walz R., Medina J.H., Izquierdo I. Short- and long-term memory: differential involvement of neurotransmitter systems and signal transduction cascades. An. Acad. Bras. Cienc. 2000, 72(3):353-364.
242. 6 receptor subtypes. Front. Cell Neurosci. 2013, 7:93.
243. 5A receptor ligands: a receptor subtype with unique therapeutical potential. Curr. Top. Med. Chem. 2010, 10(5):554-578.
244. Wallace T.L., Ballard T.M., Pouzet B., Riedel W.J., Wettstein J.G. Drug targets for cognitive enhancement in neuropsychiatric disorders. Pharmacol. Biochem. Behav. 2011, 99(2):130-145.
245. Ward B.O., Wilkinson L.S., Robbins T.W., Everitt B.J. Forebrain serotonin depletion facilitates the acquisition and performance of a conditional visual discrimination task in rats. Behav. Brain Res. 1999, 100(1-2):51-65.
246. Wardle M.C., Yang A., de Wit H. Effect of d-amphetamine on post-error slowing in healthy volunteers. Psychopharmacology (Berl.) 2012, 220(1):109-115.
247. Weiner M.W., Veitch D.P., Aisen P.S., Beckett L.A., Cairns N.J., Green R.C., et al. The Alzheimer's disease neuroimaging initiative: a review of papers published since its inception. Alzheimers Dement. 2012, 9(5):111-194.
248. 2A receptors in working memory. J. Neurosci. 2002, 22(7):2843-2854.
249. 6 antagonists. Drugs Future 2009, 34:969-975.
250. 6 receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanisms. Br. J. Pharmacol. 2012, 167(2):436-449.
251. Xu Y., Yan J., Zhou P., Li J., Gao H., Xia Y., et al. Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease. Prog. Neurobiol. 2012, 97(1):1-13.
252. Yamada K., Nabeshima T. Brain-derived neurotrophic factor/TrkB signaling in memory processes. J. Pharmacol. Sci. 2003, 91(4):267-270.
253. 1A receptor ligands with contrasting intrinsic activities. Neuropharmacology 2009, 57(5-6):567-576.
254. Yu H.Y. The prescription drug abuse epidemic. Clin. Lab. Med. 2012, 32(3):361-377.
255. 6 receptor-independent events. Toxicol. In Vitro 2011, 25(8):2035-2040.
256. Yun H.M., Rhim H. The serotonin-6 receptor as a novel therapeutic target. Exp. Neurobiol. 2011, 20(4):159-168.
257. 6 receptor through an interaction with Fyn. J. Biol. Chem. 2007, 282:5496-5505.
258. Yun H.M., Baik J.H., Kang I., Jin C., Rhim H. Physical interaction of Jab1 with human serotonin 6G-protein-coupled receptor and their possible roles in cell survival. J. Biol. Chem. 2010, 285:10016-10029.
259. Zhang G., Asgeirsdóttir H.N., Cohen S.J., Munchow A.H., Barrera M.P., Stackman R.W. Current neuroimaging techniques in Alzheimer's disease and applications in animal models. Stimulation of serotonin 2A receptors facilitates consolidation and extinction of fear memory in C57BL/6J mice. Neuropharmacology 2013, 64:403-413.
260. Zhang L., Chang R.C., Chu L.W., Mak H.K. Current neuroimaging techniques in Alzheimer's disease and applications in animal models. Am. J. Nucl. Med. Mol. Imaging 2012, 2(3):386-404.
261. Zhou W., Chen L., Paul J., Yang S., Li F., Sampson K., et al. The effects of glycogen synthase kinase-3beta in serotonin neurons. PLoS One 2012, 7(8):e43262.
262. Zola-Morgan S., Squire L.R. Neuroanatomy of memory. Ann. Rev. Neurosci. 1993, 168:547-563.